# Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

> **NCT04650724** · EARLY_PHASE1 · COMPLETED · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** T cell infusion agent targeting BCMA chimeric antigen receptor

## Key facts

- **NCT ID:** NCT04650724
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2018-12-20
- **Final completion:** 2020-10-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04650724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04650724, "Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04650724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*